Mühlethaler K, Wüthrich B, Peeters A G, Terki N, Girard J P, Frank E
Dermatologische Klinik, Universität Zürich.
Schweiz Rundsch Med Prax. 1990 Apr 3;79(14):430-6.
For controlled hyposensitization treatment over a period of three years 36 patients with confirmed grass pollen sensitization had been selected in 1986 and randomly distributed to receive preseasonal injection therapy: 23 patients were treated with an average of seven AGD (aluminium-adsorbed allergoid) injections, and 13 patients had received six TA (tyrosine-adsorbed allergoid) injections. Evaluation of the trial data collected during three years of preseasonal treatment showed the following results of tolerance and efficacy: Systemic side-reactions registered during therapy were only mild and transient and occurred in the average after 3% of the AGD injections and after 10% of the TA injections. Local reactions over 5 cm diameter were registered after 7% in the AGD group and after 9% in the TA group. Before therapy there was no significant difference (p greater than 0.05) between the groups; after three years of therapy the AGD injections had resulted in a mean net rise of specific IgG of 220% (significant, p = 0.001); during the same time, TA injections had resulted in a final net increase of 10% (not significant, p greater than 0.05). Both treatment forms did not lead to any statistically relevant changes of specific IgE values. After three years of hyposensitization treatment, patients of both groups had improved; but an advantage was documented for patients treated with AGD on the basis of scores for objective assessment as well as for registered symptom and medication scores.
在为期三年的控制性减敏治疗中,1986年选取了36例确诊为草花粉致敏的患者,并随机分配接受季前注射治疗:23例患者平均接受7次AGD(铝吸附变应原)注射,13例患者接受6次TA(酪氨酸吸附变应原)注射。对三年季前治疗期间收集的试验数据进行评估,结果显示了以下耐受性和疗效结果:治疗期间记录的全身不良反应仅为轻度且短暂,平均在3%的AGD注射后和10%的TA注射后出现。AGD组7%、TA组9%的患者出现直径超过5厘米的局部反应。治疗前两组之间无显著差异(p>0.05);经过三年治疗,AGD注射导致特异性IgG平均净升高220%(显著,p=0.001);同时,TA注射导致最终净升高10%(不显著,p>0.05)。两种治疗方式均未导致特异性IgE值发生任何具有统计学意义的变化。经过三年的减敏治疗,两组患者均有改善;但根据客观评估评分以及记录的症状和用药评分,AGD治疗的患者具有优势。